GGrantIndex
← Leaderboards

Royce Mohan

University Of Kentucky

$8,216,905
Attributed
$8,216,905
Total exposure
9
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.7M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,216,905 · 9

By mechanism

R01$5,232,681 · 3
R21$2,485,976 · 5
R56$498,248 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Kentucky

Same institution · by research overlap

Others in their field

Top investigators on “Pathway Interactions

Research focus

Pathway InteractionsInjuryProteinsProgramsPharmaceutical PreparationsCorneaMolecularIn VivoInvestigationTissuesRepairedInjuredCellsMouse ModelLeadAnalogLinkSmall MoleculeAlkaliesInflammationCorneal InjuryChemical InjuryGrantInnovation

Grant awards (28)

Corneal and Schwann cell mechanisms in vesicant injury$1,467,198
R01 · FY2025 · EY · contact PI
Targeting Corneal Schwann cells to counteract against toxin injury$249,750
R21 · FY2025 · EY · contact PI
Targeting Corneal Schwann cells to counteract against toxin injury$208,073
R21 · FY2024 · EY · contact PI
Unraveling the corneal and retinal mechanisms of chemical injury$498,248
R56 · FY2023 · EY · contact PI
Targeting Citrullination in Ocular Chemical Injury$246,000
R21 · FY2022 · EY · contact PI
Defining Corneal Schwann cells in Injury$238,620
R21 · FY2022 · EY · contact PI
Targeting Citrullination in Ocular Chemical Injury$93,090
R21 · FY2022 · EY · contact PI
Targeting Citrullination in Ocular Chemical Injury$63,699
R21 · FY2022 · EY · contact PI
Defining Corneal Schwann cells in Injury$205,000
R21 · FY2021 · EY · contact PI
Targeting Citrullination in Ocular Chemical Injury$205,000
R21 · FY2021 · EY · contact PI
PAD4 in Retinal Gliosis$239,250
R21 · FY2019 · EY · contact PI
PAD4 in Retinal Gliosis$199,375
R21 · FY2018 · EY · contact PI
PAD4 in Retinal Gliosis$197,763
R21 · FY2018 · EY · contact PI
Molecular targets of Corneal Anti-fibrosis$377,300
R01 · FY2015 · EY · contact PI
Molecular targets of Corneal Anti-fibrosis$377,300
R01 · FY2014 · EY · contact PI
Molecular targets of Corneal Anti-fibrosis$385,000
R01 · FY2013 · EY · contact PI
Molecular Targets of Corneal Antiangiogenesis$363,589
R01 · FY2011 · EY · contact PI
Molecular Targets of Corneal Antiangiogenesis$323,626
R01 · FY2010 · EY · contact PI
Novel Modular Vascular Patterning Assay for HTS$223,154
R01 · FY2010 · CA · contact PI
Molecular Targets of Corneal Antiangiogenesis$38,962
R01 · FY2010 · EY · contact PI
Molecular Targets of Corneal Antiangiogenesis$366,250
R01 · FY2009 · EY · contact PI
Novel Modular Vascular Patterning Assay for HTS$295,574
R01 · FY2009 · CA · contact PI
Molecular Targets of Corneal Anti-angiogenesis$358,925
R01 · FY2008 · EY · contact PI
Novel Modular Vascular Patterning Assay for HTS$289,553
R01 · FY2008 · CA · contact PI
Molecular Targets of Corneal Anti-angiogenesis$366,250
R01 · FY2007 · EY · contact PI
Novel High Content Vascular Patterning Assay(RMI)$51,205
R21 · FY2007 · NS · contact PI
Novel High Content Vascular Patterning Assay(RMI)$112,342
R21 · FY2006 · NS · contact PI
Novel High Content Vascular Patterning Assay(RMI)$176,809
R21 · FY2005 · NS